C3N-00559
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 55.69883641
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD030097_D2.RNA-Seq | EPN | Spinal EPN | 0.889 |
| 2 | SRR11296802 | — | — | 0.876 |
| 3 | SRR8613727 | — | D | 0.874 |
| 4 | R247 | — | — | 0.870 |
| 5 | SRR607967 | GTEX | — | 0.865 |
| 6 | MNG48 | — | — | 0.863 |
| 7 | SRR8752376 | — | — | 0.862 |
| 8 | MNG452 | — | — | 0.861 |
| 9 | MDT-AP-1354 | Med | Medulloblastoma | 0.856 |
| 10 | MDT-AP-0376 | Med | Medulloblastoma | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.020 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |